New diabetes drug may increase the risk of serious adverse events
[PRESS RELEASE 2018-11-15] The use of a new class of drugs in the treatment of type 2 diabetes, so called SGLT2 inhibitors, are linked to a twofold increased risk for lower-limb amputation as well as diabetic ketoacidosis, a serious diabetes complication. This is according to a Nordic study headed by researchers at Karolinska Institutet and published in the journal BMJ.Nearly every tenth person over the age of 18 across the world has diabetes and the number of patients is expected to increase in the next few decades. Patients with diabetes can develop several complications, such as diseases